Our company
Overview
Our Strategy
Leadership team
Board of Directors
Careers
Events
Certifications
Technology
What are Autoantibodies ?
ImmunoINSIGHTS Platform
Publications
Biotech/Pharma
Biomarker Discovery
Targeted Panels & Arrays
Bioinformatics & Data Science
Applications
Autoimmune Disease Biomarkers
Immuno-oncology Biomarkers
Infectious Disease Biomarkers
Resources
Investors
Overview
Regulatory news
Share price
Analyst research
Results, reports & presentations
Shareholder analysis
Company documents
AIM Rule 26
Corporate governance
NOMAD & advisor contacts
Contact us
Resources
Therapeutic areas
All
Autoimmune diseases
General
Immuno-oncology
Infectious diseases
News
Partnerships
Uncategorised
Diseases
Systemic lupus erythematosus (SLE)
Sjörgen’s syndrome
Systemic sclerosis (SSc)
Rheumatoid arthritis (RA)
Checkpoint inhibitors
Bispecifics
CAR-T
CART-NK
EarlyCDT Lung Cancer
COVID19
Long-Covid
Filter by type
annual report
autoantibodies
Brochure
cancer
checkpoint inhibitors
Company News
company update
Diagnostics
immunotheraphies
Indeterminate Pulmonary Nodules
Poster
Publication
Webinar
Martine Gouldstone, CEO updates investors on Oncimmune’s new strategy
Read Article
12 October 2023
Oncimmune to participate at the ASCO 2023 Meeting
Read Article
Siemens Healthineers and Oncimmune partner to improve malignancy risk assessment of indeterminate pulmonary nodules (IPNs)
Read Article
16 August 2022
16 August 2022
4 August 2022
4 August 2022
29 July 2022
21 April 2022
8 April 2022
7 March 2022
